IRADIMED CORPORATION — FY 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. The filing is an annual report, not a standalone fourth-quarter filing. IRADIMED develops and sells MRI-compatible infusion pumps, patient monitors, disposables and related services, primarily to hospitals and acute-care facilities.
Financial performance and liquidity
| Metric | FY 2017 | FY 2016 | Change |
|---|---|---|---|
| Revenue | $23.08 million | $32.50 million | Down 29.0% |
| Gross profit / margin | $17.51 million / 75.9% | $26.34 million / 81.1% | Margin down 5.2 percentage points |
| Operating income / margin | $1.29 million / 5.6% | $10.92 million / 33.6% | Down 88.2% |
| Net income | $0.50 million | $7.21 million | Down 93.1% |
| Diluted EPS | $0.04 | $0.60 | Down $0.56 |
| Cash from operating activities | $3.42 million | $9.41 million | Down $5.99 million |
- Revenue decline was driven mainly by U.S. infusion-pump sales: recognized pump systems fell to 392 from 837. Pump revenue decreased 46.6% to $13.62 million.
- Monitor revenue rose to $1.85 million from $0.29 million, while disposable IV sets and services increased 13.4% to $7.61 million. The 3880 monitor remained an early-stage product.
- Gross margin contracted amid unfavorable inventory adjustments associated with lower production, a higher international revenue share and introductory monitor pricing; favorable pump sales mix partly offset these effects.
- Operating expenses rose 5.2% to $16.23 million despite the revenue decline. FY 2017 included a $380,452 charge from modifying underwriters’ warrants and a $205,444 write-off of non-trade receivables.
- Cash and cash equivalents were $18.21 million and investments were $8.14 million at year-end; working capital was $31.03 million. Total liabilities were $6.08 million, and the balance sheet reported no debt.
- Cash from operations fell substantially, reflecting lower earnings and working-capital outflows. Investing used $1.02 million and financing used $1.90 million, primarily for $1.82 million of share repurchases.
Fourth-quarter context: Unaudited Q4 revenue was $6.70 million versus $5.99 million in Q4 2016; net income was $0.18 million versus $1.14 million. Q4 2017 included $0.85 million of income-tax expense.
Outlook, commentary and material risks
- Management expected 2018 revenue to increase, citing anticipated monitor sales and continued expansion of the critical-care strategy for pumps. It also expected higher operating expenses from sales-force growth, commissions, R&D investment and depreciation and amortization. No specific revenue or earnings guidance was provided.
- The FDA had cleared the 3860+ pump, including DERS, in December 2016 and cleared the 3880 monitor in October 2017. However, the 2014 FDA Warning Letter remained open at December 31, 2017. A required pump software field update was expected to be completed in the first half of 2018; the company accrued expected costs and said they were not expected to be significant.
- The 2017 effective tax rate was 64.2%, including a $473,899 non-cash tax expense from remeasuring deferred tax assets after U.S. tax reform. Management reported that the new revenue-recognition standard was not expected to materially affect financial statements.
- Management stated that available liquidity was expected to cover projected cash requirements for at least 12 months, while also warning that liquidity needs depend on sales, launch costs and execution. The filing identifies reliance on the infusion-pump franchise, FDA and quality-system exposure, single-source components (including the pump’s ultrasonic motor), competition in monitors, lengthy sales cycles and key-person dependence as material risks.
- The company operates from one Florida facility leased from an entity controlled by CEO Roger Susi; the related-party lease had monthly base rent of $33,171. The company also noted prior product recalls, both reported as closed, and a pending completion of the software field update.
Investor verification priorities
- Track FDA Warning Letter closure, inspection outcomes and completion of the required pump software update.
- Verify whether pump sales stabilize and whether monitor placements expand beyond the initial launch; assess recurring disposable and service revenue.
- Monitor gross margin, operating expenses and operating cash flow as revenue recovers or changes.
- Review liquidity and capital allocation, including repurchases under the remaining authorization and any need for financing.
- Review related-party arrangements and succession/key-person risk associated with CEO and founder Roger Susi.